Skip to main content Skip to main navigation menu Skip to site footer

Characteristics of COVID-19 patients with malignancies comorbidity in Sanglah General Hospital, Bali, Indonesia

  • Ida Ayu Jasminarti Dwi Kusumawardani ,
  • I Wayan Angga Suamerta Putra ,
  • Ni Wayan Candrawati ,


Abstract

Background: Cancer patients are at risk of exposing COVID-19 because of their weakened immune system, caused by tumor growth and anti-cancer therapy. Cancer patients can also increase the risk of severe infection. This study aims to determine the characteristic of COVID-19 patients with malignancies in our institution

Methods: We analyze the data of 68 COVID-19 patients with malignancies as comorbidities who were hospitalized or treated in our institution using cohort retrospective design. Variables assessed in this study include gender, age, type of malignancy, organ involved, cancer treatment, the severity of COVID-19, and outcome. Data were analyzed using SPSS version 25 for Windows and interpreted as number and percentage.

Results: Solid malignancy was the most common type (82,4%). The lung and thorax were the most common organ involved, followed by the cervix, abdomen, breast, and nasopharynx. Most patients (66.2%) with malignancy suffered from COVID-19 with mild-moderate (non-severe) symptoms and 33,8% severe symptoms. Sixteen (23.5%) patients have died. Laboratory findings showed elevated NLR and D-dimer in both severe and non-severe cases. The median NLR of all cases was 5.97. The median D-dimer was 1.61 ìg/ml. Patients with solid malignancy (35.7%) are more exposed to severe COVID-19 than the hematological type (p=0.477). Patients with malignancy who had received therapy for their cancer had more severe symptoms than those who had not received cancer therapy (41.7% vs. 25%) (p=0.147), although not statistically significant.

Conclusion: Solid malignancy was the most common type diagnosed with COVID-19. More malignancy patients experienced mild to moderate COVID-19 symptoms, and one-third of them experienced severe symptoms.

Keywords: Characteristics COVID-19 Malignancies

References

  1. Liu C, Zhao Y, Okwan-Duodu D, Basho R, Cui X. COVID-19 in cancer patients: risk, clinical features, and management. Cancer Biol Med. 2020;17(3):519-527.
  2. Herawati S, Kandarini Y, Mulyantari NK, Prabawa PY. Correlation of Neutrophil to Lymphocyte Ratio with Interleukin-10 in Diagnosis and Monitoring of Coronavirus Disease-19 Patients. Open Access Macedonian of Medical Sciences. 2022;10(B):63-66.
  3. Cavalcanti IDL, Soares JCS. Impact of COVID-19 on cancer patients: A review. Asia Pac J Clin Oncol. 2021;17(3):186-192.
  4. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020;21(3):335-337.
  5. Garassino MC, Whisenant JG, Huang LC, Trama A, Torri V, Agustoni F, et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol. 2020;21(7):914-922.
  6. Kuderer NM, Choueiri TK, Shah DP, Shyr Y, Rubinstein SM, Rivera DR, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet. 2020;395(10241):1907-1918.
  7. Bakouny Z, Hawley JE, Choueiri TK, Peters S, Rini BI, Warner JL, et al. COVID-19 and Cancer: Current Challenges and Perspectives. Cancer Cell. 2020;38(5):629-646.
  8. Scarlotta M, Simsek C, Kim AK. Liquid Biopsy in Solid Malignancy. Genet Test Mol Biomarkers. 2019;23(4):284-296.
  9. Ramdass B, Chowdhary A, Koka PS. Hematological malignancies: disease pathophysiology of leukemic stem cells. J Stem Cells. 2013;8(3-4):151-187.
  10. Dai M, Liu D, Liu M, Zhou F, Li G, Chen Z, et al. Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov. 2020;10(6):783-791.
  11. Passaro A, Bestvina C, Velez Velez M, Garassino MC, Garon E, Peters S. Severity of COVID-19 in patients with lung cancer: evidence and challenges. J Immunother Cancer. 2021;9(3):e002266.
  12. Salamanna F, Maglio M, Landini MP, Fini M. Body Localization of ACE-2: On the Trail of the Keyhole of SARS-CoV-2. Front Med (Lausanne). 2020;7:594495.
  13. Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F, et al. Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol. 2020;7(10):e737-e745.
  14. Sanchez-Pina JM, Rodríguez Rodriguez M, Castro Quismondo N, Gil Manso R, Colmenares R, Gil Alos D, et al. Clinical course and risk factors for mortality from COVID-19 in patients with haematological malignancies. Eur J Haematol. 2020;105(5):597-607.
  15. Zhang L, Zhu F, Xie L, Wang C, Wang J, Chen R, et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann Oncol. 2020;31(7):894-901.
  16. Xu JB, Xu C, Zhang RB, Wu M, Pan CK, Li XJ, et al. Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep. 2020;10(1):15058.
  17. Wiranata S, Anjani IAW, Saputra IPGS, Sadvika IGAS, Prabawa IPY, Supadmanaba IG, et al. Pretreatment Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio as a Stage Determination in Breast Cancer. Open Access Maced J Med Sci. 2020;8(B):1058- 1063
  18. Prabawa IPY, Bhargah A, Liwang F, Tandio DA, Tandio AL, Lestari AAW, et al. Pretreatment Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte Ratio (PLR) as a Predictive Value of Hematological Markers in Cervical Cancer. Asian Pac J Cancer Prev. 2019;20(3):863-868.
  19. Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.
  20. Pambudi IGPB, Suryana IK, Rai IBN, Kusumawardani IAJD, Candarawati NW, Sajinadiyasa IGK, et al. High Neutrophil to Lymphocyte Ratio, C-Reactive Protein, Procalcitonin and D-dimer as Risk Factors for Severe COVID-19. Medico-Legal Update. 2022;22(1):41-46.
  21. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-1720.
  22. Heit JA. Cancer and venous thromboembolism: scope of the problem. Cancer Control. 2005;12 Suppl 1:5-10.
  23. Beer JH, Haeberli A, Vogt A, Woodtli K, Henkel E, Furrer T, et al. Coagulation markers predict survival in cancer patients. Thromb Haemost. 2002;88(5):745-749.
  24. Ma M, Cao R, Wang W, Wang B, Yang Y, Huang Y, et al. The D-dimer level predicts the prognosis in patients with lung cancer: a systematic review and meta-analysis. J Cardiothorac Surg. 2021;16(1):243.
  25. Yu J, Li D, Lei D, Yuan F, Pei F, Zhang H, et al. Tumor-Specific D-Dimer Concentration Ranges and Influencing Factors: A Cross-Sectional Study. PLoS One. 2016;11(11):e0165390.

How to Cite

Kusumawardani, I. A. J. D., Putra, I. W. A. S., & Candrawati, N. W. (2022). Characteristics of COVID-19 patients with malignancies comorbidity in Sanglah General Hospital, Bali, Indonesia. Bali Medical Journal, 11(1), 410–413. https://doi.org/10.15562/bmj.v11i1.2972
ACM ACS APA ABNT Chicago Harvard IEEE MLA Turabian Vancouver
Download Citation
Endnote/Zotero/Mendeley (RIS) BibTeX

HTML
0

Total
21

Share

Search Panel

Ida Ayu Jasminarti Dwi Kusumawardani
Google Scholar
Pubmed
BMJ Journal

I Wayan Angga Suamerta Putra
Google Scholar
Pubmed
BMJ Journal

Ni Wayan Candrawati
Google Scholar
Pubmed
BMJ Journal